AN2 Therapeutics reports Q2 2026 results, updates timelines on three Phase 2 programs
The company is broadening its polycythemia vera trial to new sites after an FDA meeting, pushing enrollment into the fourth quarter, while enrollment continues in an M.
SEC filing